New COVID-19 preprint by Helix shows Delta and Gamma displacing Alpha in the US.
Data from our viral surveillance and testing predict Delta will be dominant in a few weeks; early evidence shows growth is faster in counties with lower vaccination rates compared to gamma.
Rapid work by the research team; clear need for viral surveillance to track mutations. Using the same methods as in the UK to track the H69/V79 mutation, we find the same pattern in the US, with a small but increasing trend since mid October
A thread on S gene drop out patterns in SARS-CoV-2 tests done at @my_helix .
Summary:
- we observe S gene drop out since mid October in US. Up to 0.5% last week.
- more sequencing of the virus is needed in the US.
https://t.co/sDY4fKMKvD
Was great to work with the @HealthyNV team on our new publication demonstrating the clinical value of primary genetic screening in the population. Thanks @renownhealth@MayoClinicCIM@drisci@my_helix for the support.
Thanks to @renownhealth, @DRIScience, @my_helix, and @MayoClinic for the support and academic contributions. Thanks to all the participants of the @HealthyNV - we can't do any of the work without you.
#COVID2019 Love the work on Antibody Tests, but before we start thinking about immunity certificates from population screening with serology we need higher specificity.
Amazing work by @my_helix research team. ~200K mito allele frequency database, 4x larger than other available tools. 47% of mito is invariant. Likely to greatly impact clinical interpretation. https://t.co/wH2jzD1irs
@ATorkamani@atulbutte@RobertCGreen
Selective constraints and pathogenicity of mitochondrial DNA variants inferred from a novel database of 196,554 unrelated individuals https://t.co/pxoHppwWBv #bioRxiv
Amazing work by @my_helix research team. ~200K mito allele frequency database, 4x larger than other available tools. 47% of mito is invariant. Likely to greatly impact clinical interpretation. https://t.co/wH2jzD1irs
@ATorkamani@atulbutte@RobertCGreen
Working together with @renownhealth and @DRIScience we used HelixMTdb to better classify the likely pathogenicity of variants suspected to cause mitochondrial disease. Read our analysis now on @biorxivpreprint https://t.co/FjUrt52YJ1
congrats to the research teams @my_helix @HealthyNV on getting this test + validation study across >50,000 exomes + > 1,000 clinical phenotypes. Some great findings both of expected results and some novel things as well.
Excited to get our work out there on rare variant analyses for thousands of phenotypes in >50k exomes across two cohorts. This was a really fun analysis to do! @my_helix @HealthyNV
Today we're thrilled to announce our partnership with AdventHealth Orlando, bringing the WholeMe study to 10,000 individuals in Florida. https://t.co/EoqvXSHJ2e
@my_helix@uk_biobank@ATorkamani@RobertCGreen@atulbutte Nice recapitulation of known results: 1) Alkaline phosphatase and ALPL which is implicated in Hypophosphatasia, 2) LDL and LDLR, APOB, PSCK9 implicated in Familial Hypercholesteremia, 3) Total Bili and UGT1A1 implicated in hyperbili diseases. also other interesting findings